Skip to Main Content
Table 4.

Prenatal DES exposure in relation to risk of invasive breast cancer among women ages ≥40 years according to parity, family history of breast cancer, use of female hormone supplements, use of oral contraceptives, and menopausal status

Exposed
Unexposed
Age-adjusted IRR (95% CI)
Person-years of follow-upCases*Person-years of follow-upCases*
Parous 19,290 43 9,941 14 1.98 (1.06-3.71) 
Nulliparous 9,901 17 3,100 1.72 (0.50-5.86) 
      
Family history 3,938 18 1,771 2.26 (0.74-6.91) 
No family history 24,899 42 11,156 13 1.83 (0.96-3.51) 
      
Ever FH use 6,677 20 3,137 1.69 (0.70-4.08) 
Never FH use 22,083 39 9,752 1.98 (0.96-4.10) 
      
Never OC use 6,088 12 2,468 — 
Ever OC use 23,073 48 10,461 16 1.63 (0.91-2.94) 
      
Premenopausal 20,587 39 8,989 2.20 (1.02-4.72) 
Postmenopausal 6,383 17 2,974 1.87 (0.72-4.83) 
Exposed
Unexposed
Age-adjusted IRR (95% CI)
Person-years of follow-upCases*Person-years of follow-upCases*
Parous 19,290 43 9,941 14 1.98 (1.06-3.71) 
Nulliparous 9,901 17 3,100 1.72 (0.50-5.86) 
      
Family history 3,938 18 1,771 2.26 (0.74-6.91) 
No family history 24,899 42 11,156 13 1.83 (0.96-3.51) 
      
Ever FH use 6,677 20 3,137 1.69 (0.70-4.08) 
Never FH use 22,083 39 9,752 1.98 (0.96-4.10) 
      
Never OC use 6,088 12 2,468 — 
Ever OC use 23,073 48 10,461 16 1.63 (0.91-2.94) 
      
Premenopausal 20,587 39 8,989 2.20 (1.02-4.72) 
Postmenopausal 6,383 17 2,974 1.87 (0.72-4.83) 

Abbreviations: FH, female hormone supplement; OC, oral contraceptives.

*

Case numbers do not sum to total because of missing data on covariates.

Close Modal

or Create an Account

Close Modal
Close Modal